Revolution Medicines Inc (RVMD)

$38.21

+0.67

(+1.78%)

Market is closed - opens 7 PM, 24 Jun 2024

Performance

  • $37.43
    $38.57
    $38.21
    downward going graph

    2.04%

    Downside

    Day's Volatility :2.96%

    Upside

    0.93%

    downward going graph
  • $15.44
    $41.21
    $38.21
    downward going graph

    59.59%

    Downside

    52 Weeks Volatility :62.53%

    Upside

    7.28%

    downward going graph

Returns

PeriodRevolution Medicines Inc
3 Months
23.78%
6 Months
40.01%
1 Year
53.02%
3 Years
16.03%

Highlights

Market Capitalization
6.2B
Book Value
$10.46
Earnings Per Share (EPS)
-3.84
Wall Street Target Price
45.55
Profit Margin
0.0%
Operating Margin TTM
-11550.31%
Return On Assets TTM
-22.11%
Return On Equity TTM
-36.17%
Revenue TTM
4.6M
Revenue Per Share TTM
0.04
Quarterly Revenue Growth YOY
-95.19999999999999%
Gross Profit TTM
-217.7M
EBITDA
-522.0M
Diluted Eps TTM
-3.84
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.12
EPS Estimate Next Year
-3.5
EPS Estimate Current Quarter
-0.75
EPS Estimate Next Quarter
-0.78

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Revolution Medicines Inc(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
16
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 19.21%

Current $38.21
Target $45.55

Technicals Summary

Sell

Neutral

Buy

Revolution Medicines Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Revolution Medicines Inc
Revolution Medicines Inc
-3.92%
40.01%
53.02%
16.03%
32.21%
Moderna, Inc.
Moderna, Inc.
-18.32%
40.58%
10.72%
-39.74%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.05%
24.38%
35.05%
97.21%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
5.92%
38.21%
77.43%
245.57%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.73%
15.66%
34.62%
148.17%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Revolution Medicines Inc
Revolution Medicines Inc
NA
NA
NA
-3.12
-0.36
-0.22
NA
10.46
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Revolution Medicines Inc
Revolution Medicines Inc
Buy
$6.2B
32.21%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • Vanguard Group Inc

    8.94%
  • Wellington Management Company LLP

    8.92%
  • BlackRock Inc

    7.46%
  • Baker Bros Advisors LP

    4.58%
  • Farallon Capital Management, L.L.C.

    4.55%
  • Nextech Invest AG

    3.82%

Corporate Announcements

  • Revolution Medicines Inc Earnings

    Revolution Medicines Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

Organization
Revolution Medicines Inc
Employees
411
CEO
Dr. Mark A. Goldsmith Ph.D.
Industry
Health Technology

FAQs